Talphera, Inc. Share Price & Technical Analysis
TLPH · $0.82 (0.00%)
Healthcare / Drug Manufacturers - Specialty & Generic
$0.82
0.00%
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
-11% return in May, 14% avg return in past 3 year May month.
-19% return in 2026, -24% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | 0% | -11% | 13% | -11% | – | – | – | – | – | – | – | -19% |
| 25 | 20% | 0% | -17% | -17% | 0% | 0% | -20% | 25% | 50% | 44% | -7% | -21% | 58% |
| 24 | 25% | 27% | -33% | -9% | 0% | -10% | 11% | 0% | -10% | 0% | -22% | -29% | -50% |
| 23 | -13% | -30% | -50% | 0% | 43% | 10% | -9% | 0% | -40% | -17% | 40% | -12% | -78% |
| 22 | -17% | -10% | -37% | -14% | -12% | 4% | -19% | 43% | -30% | -35% | -8% | 0% | -134% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$45.42M
P/E ratio
—
52W high
$1.57
52W low
$0.38
Volume
43,882
Beta
0.79
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Talphera, Inc. share price today?
- Talphera, Inc. (TLPH) last traded around $0.82 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TLPH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TLPH. Download the app for real-time alerts.
- How can I analyze Talphera, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.